Overview

* Alphatec ( ATEC ) Q3 revenue grew 30% to $197 mln, beating analyst expectations

* Adjusted EBITDA for Q3 was $26 mln, surpassing analyst estimates

* Company raises full-year revenue and profitability guidance

Outlook

* Alphatec ( ATEC ) raises full-year revenue guidance to $760 mln from $742 mln

* Company expects full-year adjusted EBITDA of $91 mln, up from $83 mln

Result Drivers

* SURGICAL REVENUE - Co attributes 31% growth in surgical revenue to continued momentum of PTP and LTP solutions

* EOS REVENUE - EOS revenue grew by 29% YoY as EOS Insight adoption increased

* NEW SURGEON USERS - Achieved 26% growth in net new surgeon users, a key leading indicator of future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $197 mln $182.8

Revenue mln (9

Analysts

)

Q3 Net -$29 mln

Income

Q3 Beat $26 mln $19.9

Adjusted mln (7

EBITDA Analysts

)

Q3 Gross 70%

Margin

Q3 70%

Adjusted

Gross

Margin

Q3 Basic -$0.19

EPS

Q3 -$15.93

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Alphatec Holdings Inc ( ATEC ) is $20.00, about 17.6% above its October 29 closing price of $16.49

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)